Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Axonics Inc before investing.
In this article, we go over a few key elements for understanding Axonics Inc’s stock price such as:
- Axonics Inc’s current stock price and volume
- Why Axonics Inc’s stock price changed recently
- Upgrades and downgrades for AXNX from analysts
- AXNX’s stock price momentum as measured by its relative strength
About Axonics Inc
(AXNX)
Before we jump into Axonics Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat bladder and bowel dysfunction. It has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10 cubic centimeters (cc) in volume, utilizes constant current stimulation, a recharge-free patient remote control and offers broad magnetic resonance imaging (MRI) access. Its SNM systems include an easy-to-use wireless patient remote control that does not require recharging or replacement batteries. It also offers a clinician programmer that guides the implanting physician through lead placement and stimulation programming.
Want to learn more about Axonics Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Axonics Inc.
What Caused Axonics Inc Stock’s Price to Dip?
Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?
One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of December 29, 2023,, no analysts have changed their rating of Axonics Inc’s stock over the last month.
Additionally, you'll want to evaluate Axonics Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Axonics Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.
Axonics Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.
Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.
Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Axonics Inc
(AXNX) by visiting AAII Stock Evaluator.
Relative Price Strength of Axonics Inc
Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.
For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.
As of December 29, 2023, Axonics Inc has a weighted four-quarter relative price strength of -4.14%, which translates to a Momentum Score of 47 and is considered to be Average.
Want to learn more about how Axonics Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.
Axonics Inc Stock Price: Bottom Line
As of January 2, 2024, Axonics Inc’s stock price is $59.71, which is down 4.05% from its previous closing price.
AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Axonics Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.
Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.
Included With AAII Platinum
at only 6.9%
Gain Since Inception. Data as of 12/31/2024.
769.3% Stock Superstars Portfolio Total Return Since Inception
U.S. Index ETF (IYY)
SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.
FREE REPORT
BECOME A MEMBER FOR ONLY $2
Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.